Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

C Braun1, M Vocanson2, J F Nicolas3

  • 1CIRI - Centre international de recherche en infectiologie (International Center for Infectiology Research), INSERM U1111, CNRS UMR 5308, 21, avenue Tony-Garnier, 69007 Lyon, France; Hospices civils de Lyon, Hôpital Femme-Mère-Enfant, service de pneumologie et allergologie pédiatriques, Bron, France.

Annales De Dermatologie Et De Venereologie
|November 30, 2020
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eczema following IL-5 inhibitors for the treatment of severe asthma with improvement after switching to an IL-4Rα mAb.

The journal of allergy and clinical immunology. In practice·2025
Same author

Dupilumab in Eosinophilic Gastrointestinal Disorders With Extraesophageal Involvement: A Pediatric Case Series and Systematic Review.

Journal of investigational allergology & clinical immunology·2025
Same author

Finite element fracture load analysis and dark-field X-ray imaging of osteoporotic and healthy vertebrae in human lumbar spine specimens.

BMC musculoskeletal disorders·2025
Same author

Allergic Signature in Delayed Cross-Hypersensitivity to all Iodinated Contrast Media.

Allergy·2025
Same author

Use of a 24-Hour Hotline vs Voicemail for Off-Hour Support During Oral Immunotherapy for Food Allergy.

Journal of investigational allergology & clinical immunology·2025
Same author

Methotrexate for atopic dermatitis: The right dosing and best-performance administration route.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same journal

2024 guidelines (S3) for the therapeutic management of patients with genital herpes.

Annales de dermatologie et de venereologie·2026
Same journal

Topical JAK inhibitors in the lichen planus spectrum: a systematic review.

Annales de dermatologie et de venereologie·2026
Same journal

2024 recommendations for the therapeutic management of anogenital warts.

Annales de dermatologie et de venereologie·2026
Same journal

Successful use of thalidomide in treating metastatic Crohn's disease.

Annales de dermatologie et de venereologie·2026
Same journal

Multiple cutaneous juvenile xanthogranuloma: a monocentric study.

Annales de dermatologie et de venereologie·2026
Same journal

Cartilage-hair-hypoplasia associated with granulomatosis induced by rubella vaccine.

Annales de dermatologie et de venereologie·2026
See all related articles
This summary is machine-generated.

Atopy involves exaggerated type-2 inflammation in diseases like eczema and asthma. Understanding diverse disease endotypes is crucial for personalized medicine approaches beyond general type-2 inflammation.

Area of Science:

  • Immunology
  • Allergy
  • Dermatology

Background:

  • Atopy is characterized by a propensity for exaggerated type-2 inflammatory responses.
  • Atopic diseases include atopic dermatitis, food allergy, asthma, and allergic rhinitis/conjunctivitis.
  • Type-2 inflammation, involving innate and adaptive immunity, is a shared characteristic of atopic diseases.

Purpose of the Study:

  • To explore the pathophysiology of atopic diseases.
  • To highlight the role of type-2 inflammation and its mediators (IL-4, IL-5, IL-13).
  • To emphasize the need for an endotype-based approach in personalized medicine for atopic conditions.

Main Methods:

  • Review of current understanding of atopic disease mechanisms.
  • Analysis of the role of type-2 cytokines and cellular inflammation.
Keywords:
Atopic dermatitisAtopieAtopyDermatite atopiqueInflammation de type 2Médecine personnaliséePersonalized medicineType-2 inflammation

Related Experiment Videos

  • Discussion of factors beyond type-2 inflammation, such as epithelial barrier dysfunction and IgE-mediated responses.

    • Main Results:

    • Type-2 inflammation is central to atopic diseases, mediated by interleukins 4, 5, and 13.
    • Not all patients respond to type-2 targeting treatments, indicating diverse underlying mechanisms.
    • Factors like epithelial barrier defects, IgE responses, and type-17 inflammation contribute to disease heterogeneity.

    Conclusions:

    • A global approach viewing atopic diseases as type-2 inflammatory conditions is fundamental but insufficient.
    • Recognizing diverse pathophysiological 'endotypes' is essential for effective, personalized treatment strategies.
    • Personalized medicine tailored to specific endotypes offers a promising future for managing atopic diseases.